Glenmark Pharmaceuticals surges on reporting rise in Q2 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 429.10, up by 14.95 points or 3.61% from its previous closing of Rs. 414.15 on the BSE.
The scrip opened at Rs. 417.00 and has touched a high and low of Rs. 434.65 and Rs. 417.00 respectively. So far 193627 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 434.65 and Rs. 410.15 respectively. The current market cap of the company is Rs. 12114.89 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.08% and 19.27% respectively.
Glenmark Pharmaceuticals reported results for second quarter ended September 30, 2022.
The company has reported 43.90% fall in its net profit at Rs 423.15 crore for Q2FY23 as compared to Rs 754.26 crore for the corresponding quarter previous year. However, total income of the company increased by 11.65% to Rs 2,524.94 crore for the quarter under review as compared to Rs 2,261.56 crore for the same quarter in the previous year.
On the consolidated basis, the company has reported marginal rise of 1.41% in its net profit at Rs 278.67 crore for the quarter under review as compared to Rs 274.81 crore for the same quarter in the previous year. Total income of the company increased by 10.79% to Rs 3,472.68 crore for the quarter under review as compared to Rs 3,134.38 crore for the same quarter in the previous year.
